| Streptomycin sulfate Chemical Properties |
| alpha |
-79～-88°(20℃/D)(c=1,H2O)(calculated on the dried basis) |
| density |
1.2302 (rough estimate) |
| refractive index |
-85 ° (C=1, H2O) |
| storage temp. |
2-8°C |
| solubility |
H2O: 0.1 g/mL, clear |
| form |
powder |
| color |
white to off-white |
| PH |
pH (100g/l, 25℃) : 4.5～7.0 |
| Water Solubility |
>=0.01 g/100 mL at 18 ºC |
| Merck |
14,8826 |
| BRN |
3894995 |
| Stability: |
Stable. Incompatible with strong oxidizing agents. |
| InChIKey |
QTENRWWVYAAPBI-YZTFXSNBSA-N |
| CAS DataBase Reference |
3810-74-0 |
|
| |
| Product Name: |
Streptomycin sulfate |
| Synonyms: |
Verstrep;O-2-Deoxy-2-(methylamino)-alpha-L-glucopyranosyl-(1->2)-O-5-deoxy-3-C-formyl-alpha-L-lyxofuranosyl-(1->4)-N,N'-bis(aminoiminomethyl)-D-streptamine sulfate;Strep-sol;Streptomyc;Streptomycin 2/3 Sulfate;2-[(1S,2R,3S,4S,5R,6S)-5-(diaminomethylideneamino)-2-[(2R,3S,4S,5R)-3-[(2R,3R,4R,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-methylamino-oxan-2-yl]oxy-4-formyl-4-hydroxy-5-methyl-oxolan-2-yl]oxy-3,4,6-trihydroxy-cyclohexyl]guanidine;D-Streptamine, O-2-deoxy-2-(methylamino)-a-L-glucopyranosyl-(1->2)-O-5-deoxy-3-C-formyl-a-L-lyxofuranosyl-(1->4)-N,N'-bis(aminoiminomethyl)-, sulfate (2:3);O-2-Deoxy-2-(methylamino)-alpha-L-glucopyranosyl-(1-2)-O-5-deoxy-3-C-formyl-alpha-L-lyxofuranosyl-(1-4)-N,N'-bis(aminoiminomethyl)-D-Streptamine sulfate (2:3) salt |
| CAS: |
3810-74-0 |
| MF: |
C21H41N7O16S |
| MW: |
679.65 |
| EINECS: |
223-286-0 |
| Product Categories: |
Aminoglycosides (Antibiotics for Research and Experimental Use);Antibiotics for Research and Experimental Use;Biochemistry;Antibiotic Explorer;AGRI-STREP;Inhibitors;AminoglycosidesPesticides;AntibioticsPesticides&Metabolites;BactericidesAntibiotics;Intermediates & Fine Chemicals;Oligosaccharides;Pharmaceuticals;API;antibiotic;Antibiotics;BacteriostaticAlphabetic;Chemical Structure;Fungicides;Pesticides;Principle;S;SN - SZ;Peptide Synthesis/Antibiotics |
| Mol File: |
3810-74-0.mol |
| |
| alpha |
-79～-88°(20℃/D)(c=1,H2O)(calculated on the dried basis) |
| density |
1.2302 (rough estimate) |
| refractive index |
-85 ° (C=1, H2O) |
| storage temp. |
2-8°C |
| solubility |
H2O: 0.1 g/mL, clear |
| form |
powder |
| color |
white to off-white |
| PH |
pH (100g/l, 25℃) : 4.5～7.0 |
| Water Solubility |
>=0.01 g/100 mL at 18 ºC |
| Merck |
14,8826 |
| BRN |
3894995 |
| Stability: |
Stable. Incompatible with strong oxidizing agents. |
| InChIKey |
QTENRWWVYAAPBI-YZTFXSNBSA-N |
| CAS DataBase Reference |
3810-74-0 |
| EPA Substance Registry System |
Streptomycin sulfate (3810-74-0) |
| |
| Streptomycin sulfate Usage And Synthesis |
| Streptomycin sulfate |
Streptomycin sulfate is the sulfate form of streptomycin. Streptomycin class antibiotics are produced by the soil-living Actinomyces Streptomyces. Streptomycin is the first emerging drug which has been proven to be an effective chemotherapy drug in treating tuberculosis. This product must be injected intramuscularly which makes it be limited for long-term application. Streptomycin, obtained from Streptomyces, is currently the most effective and also the least toxic antibiotics for application outside the gastrointestinal tract.This product is a kind of fungicides which may be due to its direct effect on the bacterial ribosome, and the resulting effective inhibition of protein synthesis. It is mainly used for treating extracellular (including the cavity) Mycobacterium tuberculosis.
Streptomycin sulfate has a strong antibacterial effect against Mycobacterium tuberculosis but has only a mild antibacterial effect on most Gram-positive cocci (such as various Streptococcus) and tuberculosis (such as Pseudomonas aeruginosa, anaerobic). However, it still has a strong antibacterial effect on many Gram negative bacteria. The product is effective in treating a variety of skin tuberculosis with an effect of inhibiting the proliferation of Mycobacterium tuberculosis and the production of toxin. Moreover, at high concentrations (> 0.4 μg/mL), it has bactericidal effect. However, Mycobacterium tuberculosis can rapidly becomes resistance to streptomycin, and thus should be combined with other anti-TB drugs. Combing streptomycin sulfate with another approved parenteral-applied efficient fungicide, isoniazid can immediately yield a significant effect on treating susceptible bacteria. It often has resurrecteding effect in some critical situations.
Using streptomycin sulfate for treatment during the first few weeks or months of treatment can achieve the largest efficacy perhaps because of parenteral application of the strain. Serum concentrations can increase rapidly thus seems to further enhance the oral administration efficacy. Even for efficient drugs like ethambutol and isoniazid can also benefit from the compatibility of this product.
Clinical studies have shown: the four-drug therapy including streptomycin, rifampin, isoniazid and pyrazinamide can produce the strongest bactericidal effect. Treating with this therapy for two months and further treatment with isoniazid and rifampicin for 4 months can yield an efficacy which is comparable to efficacy of any other kinds of therapy being used for treating susceptible bacterial infections |
|
|
|